Select Publications
Journal articles
2020, 'A Shared Electronic Health Record in a Rural Setting Maintains Hematological Cancer Services Remotely during the COVID-19 Pandemic', Blood, 136, pp. 5 - 5, http://dx.doi.org/10.1182/blood-2020-142209
,2020, 'Management and Outcomes of Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder in the PET/CT Era: A Multicentre Study from the Australasian Lymphoma Alliance', Blood, 136, pp. 36 - 38, http://dx.doi.org/10.1182/blood-2020-140665
,2020, 'Multicenter, Retrospective Evaluation of Therapeutic Efficacy of Ruxolitinib for Chronic Gvhd Treatment', Blood, 136, pp. 45 - 47, http://dx.doi.org/10.1182/blood-2020-136164
,2020, 'Trials in Progress: A Phase I Study to Evaluate the Safety and Pharmacokinetic Profiles of CB-5339 in Participants with Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Intermediate or High-Risk Myelodysplastic Syndrome', Blood, 136, pp. 21 - 21, http://dx.doi.org/10.1182/blood-2020-140636
,2020, 'Two Rare Cases of Severe Autoimmune Dyserythropoiesis without Any Underlying Haematological Malignancy or Autoimmune Disease', Blood, 136, pp. 2 - 3, http://dx.doi.org/10.1182/blood-2020-142281
,2020, 'Unrelated Donor Transplant Recipients Given Thymoglobuline Have Superior GRFS When Compared to Matched Related Donor Recipients Undergoing Transplantation without ATG', Biology of Blood and Marrow Transplantation, 26, pp. 1868 - 1875, http://dx.doi.org/10.1016/j.bbmt.2020.06.030
,2020, 'Variable CD341 recovery of cryopreserved allogeneic HPC products: Transplant implications during the COVID-19 pandemic', Blood Advances, 4, pp. 4147 - 4150, http://dx.doi.org/10.1182/bloodadvances.2020002431
,2020, 'Hematopoietic Stem Cell Transplant Recipients Surviving at Least 2 Years from Transplant Have Survival Rates Approaching Population Levels in the Modern Era of Transplantation', Biology of Blood and Marrow Transplantation, 26, pp. 1711 - 1718, http://dx.doi.org/10.1016/j.bbmt.2020.03.005
,2020, 'Selinexor in patients with relapsed or refractory diffuse large B -cell lymphoma (SADAL): a single -arm, multinational, multicentre, open -label, phase 2 trial', LANCET HAEMATOLOGY, 7, pp. E509 - E522, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000544758900006&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial', The Lancet Haematology, 7, pp. e511 - e522, http://dx.doi.org/10.1016/S2352-3026(20)30120-4
,2020, 'Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic', Internal Medicine Journal, 50, pp. 667 - 679, http://dx.doi.org/10.1111/imj.14859
,2020, 'Bone Marrow Transplant Society of Australia and New Zealand COVID-19 consensus position statement', Internal Medicine Journal, 50, pp. 774 - 775, http://dx.doi.org/10.1111/imj.14867
,2020, 'PCN325 Health Utility in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR-DLBCL) Patients - Results of a Phase II Trial with ORAL Selinexor', Value in Health, 23, pp. S479 - S480, http://dx.doi.org/10.1016/j.jval.2020.08.462
,2019, 'Reproductive outcomes following a stem cell transplant for a haematological malignancy in female cancer survivors: a systematic review and meta-analysis', Supportive Care in Cancer, 27, pp. 4451 - 4460, http://dx.doi.org/10.1007/s00520-019-05020-8
,2019, 'An Update of Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era', Blood, 134, pp. 5719 - 5719, http://dx.doi.org/10.1182/blood-2019-126547
,2019, 'HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia', Leukemia, 33, pp. 1439 - 1450, http://dx.doi.org/10.1038/s41375-018-0321-8
,2019, 'A case series of langerhans cell histiocytosis with braf testing', Pathology, 51, pp. S92 - S92, http://dx.doi.org/10.1016/j.pathol.2018.12.243
,2019, 'CLINICAL OUTCOMES FROM VENETOCLAX BASED THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL LYMPHOMAS', Hematological Oncology, 37, pp. 535 - 537, http://dx.doi.org/10.1002/hon.221_2631
,2017, 'Distinctive clinical characteristics and favorable outcomes in patients with large granular lymphocytosis after allo-HCT: 12-year follow-up data', European Journal of Haematology, 99, pp. 160 - 168, http://dx.doi.org/10.1111/ejh.12899
,2017, 'Improved prognostic stratification power of CIBMTR risk score with the addition of absolute lymphocyte and eosinophil counts at the onset of chronic GVHD', Annals of Hematology, 96, pp. 805 - 815, http://dx.doi.org/10.1007/s00277-017-2939-4
,2016, 'Single nucleotide polymorphisms in apoptosis pathway are associated with response to imatinib therapy in chronic myeloid leukemia', Journal of Translational Medicine, 14, pp. 82, http://dx.doi.org/10.1186/s12967-016-0837-5
,2015, 'Primary cutaneous mantle-cell lymphoma: A case report and literature review', Journal of Clinical Oncology, 33, pp. e104 - e108, http://dx.doi.org/10.1200/JCO.2012.47.2829
,2015, 'Mycophenolate-based graft versus host disease prophylaxis is not inferior to methotrexate in myeloablative-related donor stem cell transplantation', American Journal of Hematology, 90, pp. 392 - 399, http://dx.doi.org/10.1002/ajh.23955
,2015, 'Chronic lymphocytic leukaemia, monoclonal B-lymphocytosis and pregnancy: Five cases, a literature review and discussion of management', British Journal of Haematology, 168, pp. 350 - 360, http://dx.doi.org/10.1111/bjh.13134
,2015, 'Effectiveness of Iphone's Touch ID: KSA Case Study', INTERNATIONAL JOURNAL OF ADVANCED COMPUTER SCIENCE AND APPLICATIONS, 6, pp. 154 - 161, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000357578700022&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2014, 'Incidence, risk factors, and long-term outcomes of sclerotic graft-versus-host disease after allogeneic hematopoietic cell transplantation', Biology of Blood and Marrow Transplantation, 20, pp. 1751 - 1757, http://dx.doi.org/10.1016/j.bbmt.2014.07.001
,2014, 'Outcomes of Hematopoietic Cell Transplantation in Adult Patients with Acquired Aplastic Anemia Using Intermediate-Dose Alemtuzumab-Based Conditioning', Biology of Blood and Marrow Transplantation, 20, pp. 1722 - 1728, http://dx.doi.org/10.1016/j.bbmt.2014.06.033
,2014, 'BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase', American Journal of Hematology, 89, pp. 626 - 632, http://dx.doi.org/10.1002/ajh.23707
,2014, 'Risk stratification of organ-specific GVHD can be improved by single-nucleotide polymorphism-based risk models', Bone Marrow Transplantation, 49, pp. 649 - 656, http://dx.doi.org/10.1038/bmt.2014.20
,2014, 'Validation of national institutes of health global scoring system for chronic Graft-Versus-Host Disease (GVHD) according to overall and GVHD-specific survival', Biology of Blood and Marrow Transplantation, 20, pp. 556 - 563, http://dx.doi.org/10.1016/j.bbmt.2014.01.010
,2014, 'Chronic lymphocytic leukaemia, monoclonal B-lymphocytosis and pregnancy: Five cases, a literature review and discussion of management', British Journal of Haematology, http://dx.doi.org/10.1111/bjh.13134
,2013, 'Risk Factors For Chronic Eye and Mouth GVHD In Unrelated Hematopoietic Cell Transplantation: T Cell Depletion Is The Only Risk Factor Identified and Appears To Be Favorable', Blood, 122, pp. 4601 - 4601, http://dx.doi.org/10.1182/blood.v122.21.4601.4601
,